|Bid||16.05 x 500|
|Ask||16.40 x 800|
|Day's Range||16.15 - 16.67|
|52 Week Range||5.00 - 24.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Berkeley, California-based company said it had a loss of 45 cents. Losses, adjusted for amortization costs, came to 43 cents per share. The biopharmaceutical company posted revenue ...
Just because a stock doubles doesn't mean it's time to sell. Very often, it's still worth buying. Find out what the answer is for these three.
What Happened Dynavax Technologies Corporation (NASDAQ: DVAX ) traded up 3.7 percent Wednesday after management announced the Centers for Disease Control and Prevention will recommend HEPLISAV-B as an ...
Dynavax Technologies Corp. shares rose 2.3% in moderate Wednesday morning trade after the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices unanimously voted in ...
Volatility is the name of the game in profitable trading, and it's all the more relavant in the biotech space, which is subject to many make-or-break catalytic events . This apart, usual market-moving ...
Dynavax Technologies Corporation (NASDAQ:DVAX) announced that HEPLISAV-B™ (Hepatitis B Vaccine) for the prevention of hepatitis B in adults is now available for prescription in the United States. It is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults. "Dynavax is prepared and proud to launch our first product, HEPLISAV-B, in the United States," said Eddie Gray, chief executive officer of Dynavax.
When Dynavax Technologies Corporation’s (NASDAQ:DVAX) announced its latest earnings (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I usedRead More...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Dynavax Technologies Corp. a score of 21. Our analysis is based on comparing Dynavax Technologies Corp. with the following peers – Agenus Inc., Biogen Inc., Idera Pharmaceuticals, Inc., Merck & Co., Inc., Gilead Sciences, Inc., Momenta Pharmaceuticals, Inc., GlaxoSmithKline plc Sponsored ADR, Astrazeneca PLC Sponsored ADR, Vical ... Read more (Read more...)
Dynavax Technologies (NASDAQ:DVAX) after five years of "torturous" waiting has at long last garnered FDA approval for Heplisav-B. Cowen analyst Phil Nadeau anticipates hundreds of millions of dollars to be made in the HBV vaccine market within 5 years.
Sure, Dynavax has already chalked up huge gains. But there's still room for the biotech stock to go higher.
Dynavax Technologies Corporation (NASDAQ: DVAX ), a clinical-stage immunotherapy company, confirmed on Thursday the U.S. Food and Drug Administration approved its two-dose vaccine The company failed to ...
An easier-to-take vaccine from an East Bay company, which could shift the fight against the surging, deadly hepatitis B virus, won regulatory approval Thursday. The company has spent hundreds of millions of dollars trying to develop the vaccine over more than a dozen years. The FDA rejected Heplisav B in February 2013 and delayed approval a year ago in order to study late-arriving data more closely.
Dynavax Technologies Corporation (NASDAQ:DVAX) has won U.S. Food and Drug Administration approval for its hepatitis B vaccine, HEPLISAV, ending a more than nine-year effort to bring the vaccine to the market. Dynavax shares reacted to the FDA approval, rising nearly 16% to $23.25 in after-hours trading. Hepatitis B is an extremely infectious and potentially deadly virus affecting a wide range of adults in the United States.
Undaunted by two earlier FDA snubs, Dynavax Technologies Corporation (NASDAQ: DVAX ) is trying again with its hepatitis B vaccine, Heplisav. Will it successfully scale the hurdle the third time? Investors ...